These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 10181751)

  • 21. Clinical and economic considerations of coronary heart disease: a managed care approach. Proceedings based on presentations from two conferences, Cardiovascular Event Reduction: Defining the Role of HMG Therapy in Managed Care, held November 14-16, 1997 in Philadelphia, and Pharmacoeconomics & Outcomes Issues of Lipid Therapy, held November 5-7, 1997 in Orlando.
    Am J Manag Care; 1998 Apr; 4(4 Suppl):S168-233. PubMed ID: 10180343
    [No Abstract]   [Full Text] [Related]  

  • 22. Proposed drug-drug cost effectiveness methodology.
    Gagnon JP; Osterhaus JT
    Ann Pharmacother; 2006 Mar; 40(3):524-8. PubMed ID: 16507612
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacoeconomics in managed care pharmacy.
    Penna P
    Manag Care Interface; 2001 Aug; 14(8):53-4. PubMed ID: 11517838
    [No Abstract]   [Full Text] [Related]  

  • 24. Health economics in drug therapy management.
    Navarro RP
    Med Interface; 1995 May; 8(5):127-8, 130. PubMed ID: 10142785
    [No Abstract]   [Full Text] [Related]  

  • 25. Should the FDA regulate pharmacoeconomic studies?
    Robinson M
    HMO; 1996; 37(1):71-5. PubMed ID: 10159353
    [No Abstract]   [Full Text] [Related]  

  • 26. Value Health, Johnson & Johnson collaborate to develop disease management products.
    Health Care Strateg Manage; 1995 Aug; 13(8):9. PubMed ID: 10144168
    [No Abstract]   [Full Text] [Related]  

  • 27. Providing health economic data to managed care.
    Navarro RP
    Manag Care Interface; 1998 Sep; 11(9):62-3, 66. PubMed ID: 10187588
    [No Abstract]   [Full Text] [Related]  

  • 28. An industry in evolution.
    Blissenbach HF
    Med Interface; 1995 Oct; 8(10):80-1, 88. PubMed ID: 10152328
    [No Abstract]   [Full Text] [Related]  

  • 29. A conversation with E. Andrew Balas, M.D.
    Balas EA
    Manag Care; 1998 Feb; 7(2):37-41. PubMed ID: 10178884
    [No Abstract]   [Full Text] [Related]  

  • 30. Economic analysis of oral and topical therapies for onychomycosis of the toenails and fingernails.
    Casciano J; Amaya K; Doyle J; Arikian S; Shear N; Haspel M; Kahler K
    Manag Care; 2003 Mar; 12(3):47-54. PubMed ID: 12685377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effective use of NSAIDs: issues pertinent to coxib use in managed care.
    Fendrick AM
    Am J Manag Care; 2002 Nov; 8(17 Suppl):S529-41. PubMed ID: 12458822
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacoeconomics: historical perspective.
    Bootman JL; McGhan WF; Townsend RJ
    Ann Pharmacother; 2006 Mar; 40(3):518-9. PubMed ID: 16478813
    [No Abstract]   [Full Text] [Related]  

  • 33. Managed care cost containment involving prescription drugs. American Medical Association, Council on Ethical and Judicial Affairs.
    Food Drug Law J; 1998; 53(1):25-34. PubMed ID: 11795334
    [No Abstract]   [Full Text] [Related]  

  • 34. Pharmacoeconomics and the formulary decision-making process.
    Bakst A
    Hosp Formul; 1995 Jan; 30(1):42-50. PubMed ID: 10172201
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Disease management: linking clinical and pharmacy data.
    Drapin L
    Health Manag Technol; 1995 May; 16(6):14, 55. PubMed ID: 10142792
    [No Abstract]   [Full Text] [Related]  

  • 36. Pharmacoeconomics: a managed care perspective.
    Clouse JC
    Top Hosp Pharm Manage; 1994 Jan; 13(4):54-9. PubMed ID: 10130684
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The arrival of economic evidence in managed care formulary decisions: the unsolicited request process.
    Neumann PJ
    Med Care; 2005 Jul; 43(7 Suppl):27-32. PubMed ID: 16056006
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Application of pharmacoeconomics to formulary decision making in managed care organizations.
    Suh DC; Okpara IR; Agnese WB; Toscani M
    Am J Manag Care; 2002 Feb; 8(2):161-9. PubMed ID: 11858228
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quality of clinical and economic evidence in dossier formulary submissions.
    Colmenero F; Sullivan SD; Palmer JA; Brauer CA; Bungay K; Watkins J; Neumann PJ
    Am J Manag Care; 2007 Jul; 13(7):401-7. PubMed ID: 17620035
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug therapy: the impact of managed care.
    Hopkins J; Siu S; Cawley M; Rudd P
    Adv Pharmacol; 1998; 44():1-32. PubMed ID: 9547883
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.